VUG vs XBI

Vanguard Growth ETF vs SPDR S&P Biotech ETF

Quick take
  • VUG has the lower expense ratio at 0.03% vs 0.35% for XBI.
  • VUG pays a higher dividend yield (0.39%).

Side-by-side metrics

MetricVUGXBI
Expense ratio
Annual fee. Lower is better.
0.03%0.35%
Dividend yield
Trailing 12-month yield.
0.39%0.36%
AUM
Assets under management — bigger funds are typically more liquid.
$379.21B$10.73B
YTD return
5.99%33.79%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
1.261.10
P/E ratio
33.51
Last price
$86.83$164.01
Inception
Issuer
VanguardState Street

VUG top holdings

Top holdings · VUG
NVDANVIDIA Corp13.10%
AAPLApple Inc12.31%
MSFTMicrosoft Corp8.99%
GOOGLAlphabet Inc Class A5.95%
AVGOBroadcom Inc5.16%
AMZNAmazon.com Inc4.85%
GOOGAlphabet Inc Class C4.68%
METAMeta Platforms Inc Class A3.73%
TSLATesla Inc3.31%
LLYEli Lilly and Co2.53%
Sector breakdown · VUG
Real Estate0.9%
Consumer Cyclical11.8%
Basic Materials0.6%
Consumer Defensive1.3%
Technology55.9%
Communication Services16.4%
Financial Services4.0%
Industrials4.3%
Energy0.3%
Healthcare4.6%

XBI top holdings

Top holdings · XBI
APGEApogee Therapeutics Inc1.49%
MRNAModerna Inc1.41%
TWSTTwist Bioscience Corp1.41%
ORKAOruka Therapeutics Inc1.38%
KYMRKymera Therapeutics Inc Ordinary Shares1.36%
VKTXViking Therapeutics Inc1.30%
PRAXPraxis Precision Medicines Inc Ordinary Shares1.29%
ERASErasca Inc1.27%
RVMDRevolution Medicines Inc Ordinary Shares1.20%
RYTMRhythm Pharmaceuticals Inc1.20%
Sector breakdown · XBI
Financial Services0.5%
Healthcare99.5%

About VUG

VUG (Vanguard Growth ETF) is Large-cap US growth stocks. Managed by Vanguard, the fund carries $379.2B in assets under management, an expense ratio of 0.03%, a dividend yield of 0.39%. Its largest holding is NVIDIA Corp (NVDA), which represents 13.1% of the portfolio. Real Estate is the fund's largest sector exposure at 0.9%.

About XBI

XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.